Abstract: The present disclosure describes an immunotherapy delivery hydrogel system. The immunotherapy delivery hydrogel system can be degradable and can release therapeutic agents at a tunable rate, and in a controlled manner. The immunotherapy delivery hydrogel system includes a hydrogel matrix and cancer therapeutic agent(s) associated with the hydrogel matrix. The hydrogel system can further include tumor cell-attractant(s) conjugated to the hydrogel matrix. The tumor cell-attractant(s) and the cancer therapeutic agent(s) act synergistically to treat cancer.

Abstract: Methods and compositions for treatment of malignancies are provided. The methods utilize implantation of engineered, programmable hydrogel depots capable of long-term molecule release into close proximity of the tumor. By providing gradients of immune cell chemokines and releasing immune checkpoint inhibitors, the hydrogel implants are effective at elimination of tumor cells via immune cell-mediated cell death.